At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Let's talk about the popular WuXi Biologics (Cayman) Inc. (HKG:2269). The company's shares saw significant share price movement during recent months on the SEHK, rising to highs of HK$73.90 and falling to the lows of HK$48.65. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether WuXi Biologics (Cayman)'s current trading price of HK$52.00 reflective of the actual value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at WuXi Biologics (Cayman)’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for WuXi Biologics (Cayman)

What Is WuXi Biologics (Cayman) Worth?

WuXi Biologics (Cayman) is currently expensive based on my price multiple model, where I look at the company's price-to-earnings ratio in comparison to the industry average. I’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 47.43x is currently well-above the industry average of 23.55x, meaning that it is trading at a more expensive price relative to its peers. But, is there another opportunity to buy low in the future? Given that WuXi Biologics (Cayman)’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

What kind of growth will WuXi Biologics (Cayman) generate?

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. WuXi Biologics (Cayman)'s earnings over the next few years are expected to double, indicating a very optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? It seems like the market has well and truly priced in 2269’s positive outlook, with shares trading above industry price multiples. However, this brings up another question – is now the right time to sell? If you believe 2269 should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping an eye on 2269 for a while, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the optimistic prospect is encouraging for 2269, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

It can be quite valuable to consider what analysts expect for WuXi Biologics (Cayman) from their most recent forecasts. Luckily, you can check out what analysts are forecasting by clicking here.

If you are no longer interested in WuXi Biologics (Cayman), you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.